{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000036","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.134171+00:00","generated_at":"2026-05-15T06:45:56.147503+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmunityBio reports preliminary Q1 2026 net product revenue $44.2M, up 168% YoY, cash $381M","bullets":["Preliminary Q1 2026 net product revenue ~$44.2M, up 168% YoY and 15% sequentially from $38.3M in Q4 2025.","Cash, cash equivalents and marketable securities of $380.9M as of March 31, 2026.","ANKTIVA unit sales volume increased 168% YoY; now approved in 5 jurisdictions covering ~34 countries.","NCCN guidelines updated March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC papillary-only disease (Category 2A).","Pivotal BCG-naive NMIBC CIS trial (QUILT-2.005) fully enrolled; supplemental BLA submission on track for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000036","json":"https://secwatch.observer/filing/0001326110-26-000036.json","markdown":"https://secwatch.observer/filing/0001326110-26-000036.md","text":"https://secwatch.observer/filing/0001326110-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/ibrx-20260409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:45:56.147503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"373fd401c9005473866c9e6eeaa21b761cba6610","claim":"ImmunityBio, Inc. reported the fiscal quarter ending March 31, 2026 results: revenue approximately $44.2 million.","evidence_excerpt":"ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000036/0001326110-26-000036-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ending March 31, 2026"},{"label":"Revenue","value":"approximately $44.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}